Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

Abstract Background In clinical trials enrolling patients with type 2 diabetes (T2D) at high cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved albuminuria status and possibly mitigated kidney function loss. However, limited data are available regarding the effe...

Full description

Bibliographic Details
Main Authors: Meir Schechter, Cheli Melzer Cohen, Alisa Fishkin, Aliza Rozenberg, Ilan Yanuv, Dvora R. Sehtman-Shachar, Gabriel Chodick, Alice Clark, Trine J. Abrahamsen, Jack Lawson, Avraham Karasik, Ofri Mosenzon
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Cardiovascular Diabetology
Subjects:
GLP-1 RA
Basal insulin
Chronic kidney disease
Real world evidence
Type 2 diabetes
eGFR slope
Online Access:https://doi.org/10.1186/s12933-023-01829-0

Internet

https://doi.org/10.1186/s12933-023-01829-0

Similar Items